Features
Bicalutamide is a nonsteroidal antiandrogen devoid of other endocrine activity, which competes with androgen for the binding of androgen receptors. It does not suppress androgen production and may increase serum androgen concentrations. Bicalutamide 50 mg daily is indicated for use in combination therapy with a luteinizing hormone releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.